Key Summary Points {#FPar1}
==================

**Why carry out this study?**To generate evidence of PVP-I virucidal activity against SARS-CoV-2, the virus that causes COVID-19 disease.With no definitive treatment or vaccine available as yet for COVID-19, effective infection control measures are needed to limit virus spread.Previous studies showed the efficacy of PVP-I products against similar viruses (SARS-CoV, MERS-CoV) and a range of other viruses, but PVP-I has not yet been directly tested against SARS-CoV-2.**What was learned from the study?**All four tested PVP-I products demonstrated ≥4 log~10~ reduction of SARS-CoV-2 titres, corresponding to a ≥ 99.99% kill rate, with a contact time of 30 s. This shows the rapid virucidal activity of the PVP-I products against SARS-CoV-2.PVP-I-based disinfectants are already widely available and could be readily integrated into existing infection control protocols in both hospital and community settings.

Introduction {#Sec1}
============

Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome (SARS)-coronavirus (CoV)-2 virus, was declared a pandemic by the World Health Organization (WHO) on 11 March 2020 \[[@CR1]\]. The number of infections has grown exponentially over a short period of time \[[@CR2]\]. As of 22 June 2020, the virus has spread rapidly and infected at least 8.95 million people worldwide, causing over 468,000 deaths from the disease \[[@CR3]\].

SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA virus and belongs to the same class of beta-coronaviruses as SARS-CoV and Middle East Respiratory Syndrome (MERS)-CoV, the viruses responsible for the SARS 2003 and MERS 2012 epidemics, respectively \[[@CR4], [@CR5]\]. Current evidence indicates that human-to-human transmission primarily occurs through respiratory droplets from coughs or sneezes and/or physical contact \[[@CR6]\]. As the virus can persist on contaminated surfaces for days \[[@CR7]\], infection can occur indirectly by touch transfer of virus from these surfaces or hands to the mucosa of the mouth, nose or eyes. Thus, infection control measures, such as disinfecting surfaces and good personal and hand hygiene, are important to limit the spread of the virus.

Povidone-iodine (polyvinylpyrrolidone iodine, PVP-I) is a water-soluble complex of povidone, a carrier molecule, and iodine, which has powerful microbicidal activity. PVP-I formulations have been widely used for \> 60 years because of their broad-spectrum antimicrobial activity and established safety profile \[[@CR8], [@CR9]\]. PVP-I is on the WHO List of Essential Medicines, which identifies important medicines necessary for a functional healthcare system. PVP-I mouthwash is also included in the WHO R&D blueprint for experimental therapies against COVID-19, therefore it would be important to demonstrate its direct antiviral activity against the virus \[[@CR10]\]. In addition to its broad antibacterial and antifungal activity, PVP-I has demonstrated in vitro activity against a range of viruses \[[@CR11]\], including the related SARS-CoV \[[@CR12]\] and MERS-CoV \[[@CR13]\].

In this study, we evaluated the virucidal activity of four PVP-I products against SARS-CoV-2 using a quantitative assay, at a contact time of 30 s.

Methods {#Sec2}
=======

Four PVP-I products \[**BETADINE**^**®**^ antiseptic solution (PVP-I 10% w/v), **BETADINE**^**®**^ antiseptic skin cleanser (PVP-I 7.5% w/v), **BETADINE**^**®**^ Gargle and mouth wash (PVP-I 1.0% w/v) and **BETADINE**^**®**^ throat spray (PVP-I 0.45% w/v)\] were tested at the Animal Biosafety Level (ABSL) 3 facility in the Duke-NUS Medical School, Singapore. **BETADINE**^**®**^ Gargle and Mouth Wash was tested undiluted and at a 1:2 dilution. The test products were provided by Mundipharma Singapore Holding. Virucidal activity of PVP-I products against SARS-CoV-2 was evaluated in a viral kill time assay, adapting the protocol from the EN14476 disinfectant testing methodology which has previously been used to test the efficacy of Betadine products on SARS-CoV and MERS-CoV. A ≥ 4 log~10~ (99.99%) reduction in viral titre represents effective virucidal activity per European standards \[[@CR9], [@CR12]\]. This article does not contain any studies with human participants or animals performed by any of the authors.

Virus Culture {#Sec3}
-------------

SARS-CoV-2 (hCoV-19/Singapore/2/2020) was propagated in Vero-E6 cells (American Type Culture Collection). Vero-E6 host cells were maintained in Dulbecco's Modified Eagle Medium containing 5% fetal bovine serum (DMEM-5% FBS). To prepare the virus stocks, confluent cell monolayers were infected with SARS-CoV-2 and incubated at 37 °C, 5% CO~2~ for up to 7 days. When cytopathic effects (CPE) were evident microscopically, the supernatant was harvested, clarified by centrifugation and stored at − 80 °C.

PVP-I Cytotoxicity Assay {#Sec4}
------------------------

PVP-I cytotoxicity was tested by incubating uninfected Vero-E6 cells with tenfold serial dilutions of the PVP-I test products in DMEM-5% FBS. After incubation at 37 °C for 4 days, CPE at each dilution were observed to determine the lowest PVP-I concentration at which cytotoxic effects were absent.

PVP-I Virus Kill-Time Assay {#Sec5}
---------------------------

The exposure of the virus to PVP-I products was performed at 21 °C for 30 s to evaluate disinfectant efficacy, as previously described \[[@CR13]\]. An amount of 100 µL of virus was mixed with 700 μL of PVP-I test product, in the presence of 200 μL phosphate-buffered saline (PBS) containing 0.3 g/L BSA as an interfering substance. Virus controls with 700 µL PBS in place of the PVP-I products were included.

After the intended contact time, the reaction of PVP-I was stopped by transfer of 100-µL aliquots to 900 µL DMEM-5% FBS. Immediately, tenfold serial dilutions were performed and 100 µL of each dilution was used to inoculate Vero-E6 cells (in quadruplicate) in a 96-well microtitre plate. Due to the immediate titration, no after-effect of the test product could occur, as described earlier \[[@CR9]\]. The plates were incubated at 37 °C for 4 days before CPE assessment. Viral titres were calculated as median tissue culture infectious dose (TCID~50~/mL) using the Spearman--Kärber method \[[@CR14], [@CR15]\].

Results {#Sec6}
=======

The viral kill time assay was performed after first evaluating the cytotoxicity of the products to the Vero-E6 cells. The antiseptic solution, hand sanitiser, throat spray and gargle/mouthwash were non-cytotoxic to the Vero-E6 at dilutions ≥ 1:100 and skin cleanser at dilutions ≥ 1:1000. This was taken into consideration when the kill time assay was performed.

Initial testing was carried out at 120 s to evaluate the efficacy of the various PVP-I products against the SARS-CoV-2 and to optimise the assay (Supplementary Table S1). No CPE was observed after SARS-CoV-2 exposure to PVP-I products. Due to the cytotoxicity of the products in Vero-E6 cells, the limit of detection of the assay was 3 × 10^3^ TCID~50~/mL. This demonstrated that all the test products were effective against the SARS-CoV-2 virus at 2 min.

To determine the virucidal activity of the product (≥ 4 log~10~ reduction in viral titres), the efficacy of the PVP-I products against the SARS-CoV-2 virus was tested at an exposure time of 30 s, mandated by the European Chemicals Agency (ECHA) guidelines \[[@CR16]\] to demonstrate virucidal efficacy of disinfectants for use in hospitals and at home. All PVP-I products tested at 30 s demonstrated a ≥ 4 log~10~ reduction of SARS-CoV-2 titres, corresponding to a ≥ 99.99% kill for all the tested products, indicating rapid virucidal activity \[[@CR16]\], and also meeting the ECHA time-points for disinfectant efficacy (Table [1](#Tab1){ref-type="table"}).Table 1Virucidal activity of PVP-I products against SARS-CoV-2 virus with 30 s contact timePVP-I productReduction in viral titres\
(log~10~ TCID~50~/mL)Antiseptic solution (PVP-I 10.0%)≥ 4.00Throat spray (PVP-I 0.45%)≥ 4.00Skin cleanser (PVP-I 7.5%)≥ 4.00Gargle/mouth wash (PVP-I 1.0%)≥ 4.00Gargle/mouth wash (PVP-I 1.0%, 1:2 dilution)≥ 4.00Data are presented as log~10~ reductions in viral titres compared to control. The results demonstrate the efficacy and virucidal activity of PVP-I against SARS-CoV-2 in 30 s of exposure. Viral titre values ranged from 1.5 × 10^7^ to 1 × 10^8^ TCID~50~/mL. Results presented are from three independent experiments (*n* = 3)

Discussion {#Sec7}
==========

There are currently no established effective therapies or vaccines for COVID-19 infection despite many ongoing clinical trials \[[@CR17]\]. Hence, treatment for COVID-19 patients relies mostly on supportive care, mechanical ventilation and/or medication previously employed against other coronaviruses \[[@CR17]\]. Like SARS-CoV, SARS-CoV-2 initially appeared to spread by droplet transmission and direct/indirect contact with symptomatic infected persons. However, asymptomatic and pre-symptomatic persons infected with SARS-CoV-2 can transmit the virus \[[@CR18]\]. Moreover, the virus appears more contagious compared to SARS-CoV \[[@CR19]\].

Besides physical distancing, preventive measures, such as personal hygiene and frequent disinfection of high-touch surfaces in public spaces and healthcare facilities, are important non-therapeutic interventions to reduce the risk of person-to-person transmission in the community and to protect healthcare workers. The formulations tested have different complementary roles in infection control, including hand and oral hygiene. Firstly, hand hygiene protocols recommended by WHO \[[@CR6]\] can be augmented by using disinfectants with proven in vitro virucidal activity against SARS-CoV-2, as demonstrated with PVP-I in this study. An earlier hand hygiene simulation study demonstrated superior in vivo efficacy of a PVP-I product compared with soft soap or chlorhexidine against the non-pathogenic murine norovirus (MNV) \[[@CR20]\]. MNV, a non-enveloped virus, has been used as a model test virus in in vivo simulations for biosafety reasons, and is known to be more resilient to antiseptics than enveloped viruses, such as CoVs \[[@CR20]\].

Secondly, given the potential for SARS-CoV-2 infection via the oral and nasal mucosa, besides masks, additional respiratory hygiene measures such as throat sprays or gargling can be considered to reduce the risk of SARS-CoV-2 transmission via these routes \[[@CR9]\]. COVID-19-related guidelines from several organisations, including the Australian Dental Association and the US Centers for Disease Control and Prevention, have recommended using a pre-procedural mouthwash with products such as PVP-I \[[@CR21], [@CR22]\]. A study in Japan showed that, in patients with chronic respiratory diseases, the incidence of episodes of acute exacerbation of chronic respiratory infections decreased significantly after starting regular use of povidone-iodine gargle \[[@CR23]\]. Recent studies have shown that SARS-CoV-2 virus shedding is highest during early disease stages and occurs mostly in the upper respiratory tract \[[@CR24], [@CR25]\]. Considering these factors, both frequent hand washing and oral hygiene through gargling could help minimise the risk of infections \[[@CR26]\].

A recent study tested the stability of SARS-CoV-2 under various environmental conditions, including exposure to PVP-I and other disinfectants for 5, 15 and 30 min \[[@CR7]\]. The results showed that SARS-CoV-2 could remain viable for as long as 6--7 days on some surfaces (stainless steel and plastic), but that it could be inactivated by a number of common disinfectants. The virus was undetectable with exposure times of 5 min or longer when tested with PVP-I (7.5%), indicating potential usage in disinfection procedures \[[@CR7]\]. Previous studies with PVP-I products on SARS-CoV and MERS-CoV demonstrated rapid virucidal activity in the presence of interfering substances such as erythrocytes to simulate organic soiling ('dirty' conditions). There was no difference observed in the log kill of the viruses in clean versus dirty conditions, indicating that interfering substances do not decrease the antiviral activity of PVP-I \[[@CR9], [@CR13]\]. In these studies, PVP-I was able to rapidly inactivate (≥ 4 log~10~ reduction in TCID~50~/mL in virus titres) the SARS-CoV and MERS-CoV within contact times of 15 s.

Conclusion {#Sec8}
==========

The broad-spectrum antimicrobial and rapid virucidal activity of PVP-I products against SARS-CoV-2 suggests its importance in infection control. As an additional protective barrier to the PPE, these products may help reduce disease transmission. PVP-I is easily administered and has been used in both the hospital and community settings for \> 60 years and can thus be readily integrated into existing infection control protocols. PVP-I-based products can be used as part of infection control measures during the COVID-19 pandemic \[[@CR27]--[@CR29]\]. In summary, the use of PVP-I products can augment health and hygiene measures to reduce the spread of COVID-19 in the community.
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